FDA Updates Lumateperone Label With Relapse-Prevention Data - Summary - MDSpire

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

  • By

  • Kathryn Wighton

  • April 29, 2026

  • 2 min

Share

Objective:

To provide long-term clinical data supporting the use of lumateperone in maintaining stability and reducing relapse risk in adults with schizophrenia.

Key Findings:
  • Lumateperone significantly prolonged time to relapse compared to placebo (p=0.0002).
  • Reduced risk of relapse by 63% (hazard ratio, 0.37).
  • 84% of patients receiving lumateperone remained relapse-free at 6 months.
  • Significantly delayed time to all-cause treatment discontinuation.
  • Common treatment-related adverse event was headache, occurring in at least 5% of patients.
Interpretation:

Lumateperone demonstrates efficacy in preventing relapse in schizophrenia, with a favorable safety profile and no new safety concerns identified.

Limitations:
  • The exact mechanism of action of lumateperone is not fully understood.
  • Long-term effects beyond 12 months are not assessed.
Conclusion:

The label update reinforces lumateperone's role in maintaining disease stability in schizophrenia, alongside its existing approvals for other psychiatric conditions.

Original Source(s)

FDA Updates Lumateperone Label With Relapse-Prevention Data

  • by Kathryn Wighton

  • April 29, 2026

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Network structure of non-suicidal self-injury, alcohol and food addiction, and motivation in bus drivers